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Summary
Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the 
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the 
developmental pathway by which such antibodies are generated and acquire the requisite 
molecular characteristics for neutralization. Twelve somatically related neutralizing antibodies 
(CAP256-VRC26.01-12) were isolated from CAPRISA-donor CAP256; each antibody contained 
the protruding tyrosine-sulfated, anionic antigen-binding loop (CDR H3) characteristic of this 
category of antibodies. Their unmutated ancestor emerged between weeks 30–38 post-infection 
with a 35-residue CDR H3, and neutralized the virus that superinfected this individual 15 weeks 
after initial infection. Improved neutralization breadth occurred by week 59 with modest affinity 
maturation, and was preceded by extensive diversification of the virus population. HIV-1 V1V2-
directed neutralizing antibodies can thus develop relatively rapidly through initial selection of B 
cells with a long CDR H3, and limited subsequent somatic hypermutation, an important vaccine 
insight.
Developmental pathways of antibodies that neutralize HIV-1 represent potential templates to 
guide vaccine strategies, if their constituent molecular events were understood and could be 
reproduced1–3. Virtually all HIV-1 infected individuals mount a potent antibody response 
within months of infection, but this response preferentially neutralizes autologous virus, 
which rapidly escapes4,5. Cross-reactive antibodies capable of neutralizing most HIV-1 
strains arise in only ~20% of donors after 2–3 years of infection6–9. An understanding of the 
development of broadly neutralizing antibody (NAb) lineages in such donors could provide 
a roadmap for vaccine design.
One means to obtain such a roadmap is through isolation of broadly cross-reactive NAbs, 
characterization of their genetic sequence and molecular properties, and examination of the 
B cell genetic record with next-generation sequencing (NGS)10–14. The greatest insight can 
be gained with longitudinal sampling from early after the time of HIV-1 infection15. This 
allows for a genetic delineation of the molecular evolution leading from an unmutated 
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ancestor antibody through affinity maturation to acquisition of neutralization breadth. In 
principle, such a roadmap should link antibody molecular characteristics to the genetic 
development that a successful vaccine would retrace.
NAbs to the V1V2 region of the HIV-1 viral spike are among the most prevalent cross-
reactive antibodies elicited by natural infection6,16–18 and have been isolated from several 
donors19–21. These antibodies have long heavy-chain complementarity-determining region 3 
loops (CDR H3s) that are protruding, anionic, and often tyrosine sulfated22,23. These CDR 
H3s penetrate the HIV-1 glycan shield, recognizing a quaternary glycopeptide epitope at the 
apex of the HIV-1 spike that is formed by V1V2s from at least two gp120 protomers22–24. 
Here we employ antibody isolation, B-cell NGS, structural characterization, and viral single-
genome analysis (SGA) to delineate longitudinal interactions between the developing 
antibody and autologous virus within donor CAP256, who showed evidence of V1V2-
mediated neutralization breadth after one year18,25,26. Our results define the molecular 
requirements and genetic pathways that lead to V1V2-directed neutralization, providing a 
template for their vaccine elicitation.
Antibody isolation and characterization
Donor CAP256 peripheral blood mononuclear cells (PBMCs) sampled 59, 119 and 206 
weeks post-infection were used to isolate 12 monoclonal antibodies by high-throughput B 
cell culture, functional screening by microneutralization, and reverse transcription-PCR of 
antibody variable regions27,28 (Fig. 1a). All 12 were somatically related and distinguished 
by long CDR H3s of 35–37 amino acids (Kabat29 numbering) (Fig. 1b, Extended Data Fig. 
1a). The heavy and light chains exhibited somatic mutation of 4–15% from their germline-
encoded V-genes, VH3-30 and Vλ1-51, respectively (Extended Data Fig. 1 and Extended 
Data Table 1). When these antibodies were reconstituted as IgG1s, they showed varying 
degrees of heterologous virus neutralization and were extremely potent against many 
subtype A and C strains (Fig. 1b–c, Extended Data Fig. 2, and Supplementary Fig. 1). 
Importantly, the combination of all 12 antibodies recapitulated plasma neutralization 
(Supplementary Fig. 2), indicating the CAP256-VRC26 antibody lineage to be responsible 
for the neutralization breadth and potency of donor CAP256.
To map the epitope of the CAP256-VRC26 antibodies, we employed neutralization 
fingerprints18; binding assays for HIV-1 Envelope (Env) in soluble, cell surface30, and viral 
particle31 contexts; and negative stain electron microscopy (EM) of Fab CAP256-VRC26.09 
bound to a soluble cleaved version of the HIV-1 spike24,32,33 (Fig. 2a–c, Supplementary Fig. 
3, Extended Data Figs. 3–4). Recognition of Env by CAP256-VRC26 antibodies was similar 
to PG9-class NAbs that recognize the trimeric V1V2 cap24, with high specificity for the Env 
native quaternary conformation and one Fab bound per trimer (Fig. 2c, left and Extended 
Data Fig. 4). Neutralization activity of CAP256-VRC26 antibodies was reduced or knocked 
out by Env mutations in V1V2 strands B and C (Fig. 2d), much like the CAP256 plasma25,26 
and PG9-class NAbs22,23,34; though unlike PG9, the CAP256-VRC26 antibodies were only 
partially and variably sensitive to loss of glycans at N160 and N156 (Fig. 2d and Extended 
Data Fig. 5). Overall, these data indicated the epitope to be at the membrane-distal apex of 
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the HIV-1 spike close to the trimer axis (Fig. 2e), providing a structural explanation for the 
observed quaternary specificity.
Origin and development of the lineage
To obtain a genetic record of the CAP256-VRC26 antibody lineage, we analyzed B cell-
immunoglobulin transcripts at eight time points between 15 and 206 weeks post-infection by 
454 pyrosequencing. Although no CAP256-VRC26 lineage-related transcripts were detected 
at 15 and 30 weeks, related heavy chain and light chain transcripts were found at all later 
time points (Fig. 3a). To track longitudinal prevalence, we utilized identity-divergence plots 
of all heavy chain reads assigned to the same VH3-30 germline gene as the isolated 
antibodies. Using CAP256-VRC26.01 or CAP256-VRC26.08 as the identity referents, 
segregated islands of related heavy chain sequences first appeared at week 38 (Fig. 3b). For 
all 12 antibodies, the prevalence and identity of related sequences peaked close to the time 
of the antibody isolation (Supplementary Fig. 4). To obtain additional antibody lineage data, 
we performed linked VH:VL paired sequencing35 at five time points (Fig. 3a and 
Supplementary Table 1). Of 157 unique CAP256-VRC26 pairs, 7 matched either heavy or 
light chain sequences present in the 454 pyrosequencing data, including 2 for which both 
heavy and light chain sequences had previously been captured (Fig. 3c).
Maximum-likelihood phylogenetic trees were constructed using the isolated antibodies and 
the 454 data (Fig. 3c). The lineage bifurcates early, with one branch leading to CAP256-
VRC26.01 and a second developing into CAP256-VRC26.02-12. The unmutated common 
ancestors (UCAs) for the heavy and light chain were inferred from the phylogenetic trees 
(Fig. 3c). For the light chain, the UCA had a 12-residue CDR L3, as in CAP256-VRC26.01, 
and for the heavy chain, the inferred UCA had a 35-residue CDR H3 (Extended Data Fig. 6), 
likely the result of VDJ recombination with a single D-gene, IgHD3-3*01 and N-nucleotide 
insertions of 34 and 31 nucleotides at each junction (Supplementary Fig. 5). This inferred 
UCA was further supported by the identification of many low-divergence sequences in week 
38 heavy chain data, five of which had only two amino acid differences from the inferred 
UCA (Extended Data Fig. 6). Thus, the longitudinal NGS analysis established the first 
appearance of the CAP256-VRC26 lineage; defined the UCA, the product of gene 
recombination in the ancestor B cell of the lineage; and provided a genetic record of the 
development of this lineage over four years.
Structures of CAP256-VRC26 antibodies
To define the structural characteristics of CAP256-VRC26 lineage development, we 
determined crystal structures for Fabs of the UCA and six antibodies from weeks 59, 119 
and 206 (Fig. 4, Supplementary Table 2, and Supplementary Fig. 6a). The mature CDR H3s 
protruded ~20Å above the antigen-combining surface of the heavy chain and contained a 2-
stranded β-sheet, O-sulfated tyrosines, and an intra-CDR H3 disulfide bond (Fig. 4a–b). The 
CDR H3s of the UCA and CAP256-VRC26.01 lacked a CDR H3 disulfide bond, exhibited 
greater disorder, and were positioned more proximal to the light chain (Fig 4c); the 
appearance of the disulfide bond correlated with adoption of the mature CDR H3 orientation 
(Fig 4c, Supplementary Fig. 6b, and Extended Data Fig. 7a). Mutation to remove the 
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relevant Cys residues in VRC26.03 resulted in loss of neutralization potency and breadth 
(Extended Data Fig. 7b–c). Additionally, the appearance of CDR H3 cysteines coincided 
with a glycine to arginine mutation at the base of the CDR H3, possibly limiting flexibility 
of the mature antibodies (Extended Data Fig. 7a–b and Supplementary Fig. 7). Overall, the 
CAP256-VRC26 lineage begins with an anionic protruding CDR H3 with structural 
properties similar to previously determined V1V2-directed broadly NAbs. Development 
over four years involves the introduction of almost 20 light chain and over 30 heavy chain 
mutations, including a disulfide bond. The CDR H3 changes its overall orientation while 
losing negative charge and maintaining tyrosine sulfation (Fig. 4b–c, right).
HIV Env evolution during NAb development
To gain insight into the temporal HIV-1 Env changes driving the development of the 
CAP256-VRC26 lineage, we used SGA to determine viral sequences over ~3 years. 
CAP256 Env sequences showed high levels of diversity driven, in part, by recombination 
between the superinfecting virus (SU) that was first detected 15 weeks post-infection, and 
the primary infecting virus (PI)26 (Fig. 5a, Supplementary Figs. 8, 9). Differences between 
the PI and SU Env sequences included V2 residues 165 and 169, and an N160 glycan in the 
SU that was not present in the PI (Fig 5b, Extended Data Fig. 8a–b). Notably, compared to 
the PI, the SU contained V2 residues that are more commonly found among circulating 
viruses (Extended Data Fig 8a). All 12 antibodies neutralized the SU, and, with the 
exception of CAP256-VRC26.06, failed to neutralize the PI, suggesting the SU V1V2 
initially engaged the naive B cell of the CAP256-VRC26 lineage (Fig. 5d, Extended Data 
Fig. 8c, and Supplementary Fig. 10).
Before the CAP256-VRC26 antibodies developed, most Env sequences had V1V2 regions 
derived from the PI (Fig. 5a–c and Supplementary Fig. 8–9) and were therefore largely 
neutralization resistant (Fig. 5d and Supplementary Fig. 10). Among SU-like sequences, a 
rare K169I mutation arose under strong directional selection (Supplementary Table 3) as the 
CAP256-VRC26 lineage emerged and rendered the SU resistant to only the earliest antibody 
(Extended Data Fig. 8d–e), suggesting that CAP256-VRC26.01-like antibodies drove this 
viral escape, followed by maturation of the lineage to tolerate I169. At 48 weeks, the viral 
population underwent a significant shift (Fig 5a and Supplementary Figs. 8–9), with the SU-
like V1V2 dominating just prior to the development of neutralization breadth. Neutralization 
of Env clones by later antibodies (CAP256-VRC26.02-12) tracked with the presence of SU-
like V1V2 sequences (black bar, Fig 5c) until escape occurred through mutations at 
positions 166 or 169 (Fig. 5c–d, Extended Data Figs. 8d). These mutations resulted in a net 
charge change in the V2 epitope (+3 to 0, Fig. 5c, Extended Data Fig. 8b) concomitant with 
the antibody CDR H3s becoming less acidic over time (−10 to −4, Fig. 4 and Extended Data 
Fig. 9) suggesting co-evolution of the viral epitope and the antibody paratope. Overall, these 
results highlight the interplay between virus and antibody, with the SU-like V1V2 epitope 
stimulating expansion of the CAP256-VRC26 lineage.
Doria-Rose et al. Page 5













Rapid development of CAP256-VRC26.01
To gain insight into the development of V1V2-directed neutralization, we focused on the 
early antibody CAP256-VRC26.01, isolated at week 59, which neutralized 30% of clade C 
viruses and showed cross-clade neutralization of nearly 20% (Supplementary Fig 1). 
Notably, this week 59 time point was 44 weeks after superinfection and only 21 weeks after 
the CAP256-VRC26 lineage was first detected by NGS. We also inferred heavy and light 
chains for two developmental intermediates (VRC26-I1 and VRC26-I2) (Fig. 6a and 
Extended Data Fig. 1) and characterized their function along with the UCA (Fig. 6b–e): The 
UCA bound and neutralized the SU weakly, but did not bind nor neutralize heterologous 
viruses. VRC26-I1, VRC26-I2 and CAP256-VRC26.01 demonstrated progressively greater 
binding and neutralization, with VRC26-I1 neutralizing 2 of 7 strains and VRC26-I2 
neutralizing 6 of 7 strains (Fig 6e), with dependence on residues in V2 (Fig 6c). 
Interestingly, the PI was neither bound nor neutralized by the UCA, intermediates, or 
CAP256-VRC26.01 (Fig 6c and Supplementary Fig 11). These data provide further 
evidence that the CAP256-VRC26 lineage was initiated by interaction with an SU-like 
V1V2. Subsequent affinity maturation, focused in CDR H3 (Fig. 6f and Extended Data 
Table 1), allowed for progressively greater binding and neutralization with increased viral 
diversity preceding the emergence of neutralization breadth. Based on the inferred UCA, 
CAP256-VRC26.01 diverged 11% from germline heavy chain and 7% from germline light 
chain (Fig. 6f). Thus, once an appropriate gene recombination allows for B-cell receptor 
recognition of the trimeric V1V2 epitope, development of cross-reactive neutralization can 
be achieved with moderate somatic mutation in a matter of months.
Vaccine implications
The V1V2 region of HIV-1 is a common target of serum NAbs6,16–18. In the RV144 Thai 
vaccine trial, an increased level of binding antibodies to the V1V2 region was associated 
with a reduced risk of infection36 and viral sieve analysis showed immune pressure in the 
same region37. While the vaccine in the RV144 trial did not elicit broadly neutralizing 
V1V2-directed antibodies similar to those described here and elsewhere19–21, a more 
effective vaccine would ideally elicit cross-reactive NAbs 1–3,38. Previously described V1V2 
antibodies, and the CAP256-VRC26 lineage, all have long CDR H3 regions that are 
necessary to penetrate the glycan shield and engage a V1V2 epitope (Extended Data Table 
1). An important unanswered question has been whether these long CDR H3s are fully 
formed by VDJ recombination, as has been seen in HIV-uninfected donors39, or emerge by 
insertions during the process of affinity maturation. We show here that the 35-residue CDR 
H3 of the CAP256-VRC26 UCA was produced during initial gene rearrangement and 
therefore existed at the level of the naive B cell receptor.
A potential rate-limiting developmental step in the CAP256-VRC26 lineage is the gene 
rearrangement that generated its UCA. By one estimate, human B cells with recombined 
antibody genes encoding long (≥ 24aa, IMGT40 definition) or very long (≥28aa) CDR H3s 
constitute ~3.5% and 0.4%, respectively, of naïve B cells39. These long B cell receptors 
have been associated with autoreactivity, and are subject to both central and peripheral 
deletion, resulting in an even smaller population of IgG+ memory B cells39,41. We therefore 
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tested the UCA and all 12 CAP256-VRC26 cloned antibodies for autoreactivity42. The UCA 
and mature CAP256-VRC26 antibodies demonstrated little or no reactivity on Hep2 cells or 
with cardiolipin (Extended Data Fig. 6b–c). In addition, NGS of CAP256 peripheral B cells 
indicated that <0.4% of sequences had CDR H3s of ≥28aa (Extended Data Fig. 6d) 
suggesting that this donor did not have an unusually high frequency of clonal lineages with 
long CDR H3 regions.
We also inferred the virological events leading to the stimulation and evolution of the 
CAP256-VRC26 lineage by the superinfecting virus. Similar to the CH103 CD4-binding site 
lineage in donor CH50515, the autologous virus in CAP256 showed extensive diversification 
prior to the development of breadth. Subsequent antibody-virus interactions appeared to 
drive somatic mutation and development of cross-reactive neutralization. Finally, the 
ontogeny of V1V2-directed NAbs revealed by the CAP256-VRC26 lineage suggests that 
neutralization potency and breadth can be achieved without extraordinary levels of somatic 
hypermutation. While some NAbs appear to require years of maturation1,3,43,44, we show 
that a V1V2-directed B cell lineage can acquire HIV-1 neutralization breadth within months 
rather than years. The critical event appears to be an uncommon gene rearrangement that 
produces a B-cell receptor with protruding, tyrosine-sulfated, anionic CDR H3. Identifying 
features of antigens able to engage naive B cells with such CDR H3s is a critical step in 
design of vaccines targeting V1V2. Such antigens could be screened for binding to the UCA 
versions of NAbs as an indicator of the ability to engage an appropriate naïve B cell 
receptor. This work also suggests that although an appropriate trimeric V1V2 construct may 
elicit neutralizing V1V2 antibodies, sequential immunogens that mirror viral evolution may 
be needed to drive the development of breadth. Overall, the precise delineation of the 
developmental pathway for the CAP256-VRC26 lineage should provide a basis for attempts 
to elicit broad V1V2-directed HIV-1-neutralizing antibodies.
Full Methods
Study subject
CAPRISA participant CAP256 was enrolled into the CAPRISA Acute Infection study 51 
that was established in 2004 in KwaZulu-Natal, South Africa for follow-up and subsequent 
identification of HIV seroconversion. CAP256 was one of the 7 women in this cohort who 
developed neutralization breadth 6. The CAPRISA 002 Acute Infection study was reviewed 
and approved by the research ethics committees of the University of KwaZulu-Natal 
(E013/04), the University of Cape Town (025/2004), and the University of the 
Witwatersrand (MM040202). CAP256 provided written informed consent for study 
participation. Samples were drawn between 2005–2009.
Isolation and expression of CAP256-VRC26 family genes
PBMC isolated from CAP256 blood draws at weeks 59, 119, and 206 were stained and 
sorted for IgG+ B cells on a FACS Aria II as described in 18. Cells were plated at 2 B cells/
well in 384 well plates and cultured for 14 days in the presence of IL-2, IL-21, and CD40L-
expressing irradiated feeder cells, as described in27,45. Culture supernatants were screened 
by microneutralization as described in52 against HIV-1 ZM53.12 and CAP45.G3 Env-
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pseudoviruses. Kappa and lambda light chain gene and IgG heavy chain gene variable 
regions were amplified from neutralization-positive wells, subcloned, expressed, and 
purified as described in 18. Heavy chains were reconstituted as IgG1. The efficiency of 
cloning was as follows. For week 59, 15000 B cells (7500 wells) were plated, 8.3% of wells 
produced IgG, 4 were positive in microneutralization, and one heavy-light chain pair was 
recovered. For week 119, 45000 B cells were plated, 48% of wells produced IgG, 49 wells 
were positive in microneutralization, and 8 heavy-light chain pairs were recovered. For 
week 206, 42000 B cells were plated, 29% of wells produced IgG, 34 wells were positive in 
microneutralization, and 3 heavy-light chain pairs were recovered.
The antibodies are numbered CAP256-VRC26.01-.12 in order of the timepoint of the 
sample from which they were isolated, and then the degree of heavy chain somatic mutation.
Neutralization assays
Single round of replication Env-pseudoviruses were prepared, titered, and used to infect 
TZM-bl target cells as described previously46,47. Neutralization breadth of CAP256-
VRC26.01, 03, .06, and .08 were determined using a previously described 18,53 panel of 194 
geographically and genetically diverse Env-pseudoviruses representing the major subtypes 
and circulating recombinant forms. The remaining antibodies were assayed on a subset of 
this panel. The data were calculated as a reduction in luminescence units compared with 
control wells, and reported as 50% inhibitory concentration (IC50) in in micrograms per 
microlitre for monoclonal antibodies, or reciprocal dilution (ID50) for plasma samples.
Neutralization fingerprints
Due to the high sequence variability of HIV-1 Env, different viral strains may exhibit 
different neutralization sensitivities to the same antibody, and this pattern of neutralization 
variation can be used to define the neutralization fingerprint for a given antibody. Namely, 
the neutralization fingerprint of an antibody is defined as the rank-order of neutralization 
potencies for the antibody against a set of diverse viral strains18.
The correlations between the neutralization fingerprints of the CAP256-VRC26 antibodies 
and the neutralization patterns of four longitudinal serum timepoints (at 59, 106, 159, and 
220 weeks post infection) were computed over a set of 29 HIV-1 strains (6535.3, AC10.29, 
CAAN.A2, CAP210.E8, CAP244.D3, CAP45.G3, DU156.12, DU172.17, DU422.01, PVO.
04, Q168.a2, Q23.17, Q259.d2.17, Q461.e2, Q769.d22, Q842.d12, QH0692.42, REJO.67, 
RHPA.7, SC422.8, THRO.18, TRJO.58, TRO.11, WITO.33, ZM109.4, ZM135.10a, 
ZM197.7, ZM233.6, ZM53.12) 18. The correlations between the neutralization potencies of 
the CAP256-VRC26 antibodies and a reference set of antibodies targeting the four major 
sites of vulnerability, with at most two antibodies per unique donor, were computed over a 
set of 41 HIV-1 strains (6535.3, 0260.v5.c36, 6405.v4.c34, AC10.29, C1080.c3, CAAN.A2, 
CAP210.E8, CAP244.D3, CAP45.G3, CNE3, DU156.12, DU172.17, DU422.01, 
KER2008.12, KER2018.11, MB201.A1, MB539.2B7, PVO.04, Q168.a2, Q23.17, Q259.17, 
Q461.e2, Q769.d22, Q842.d12, QH0692.42, REJO.67, RHPA.7, RW020.2, SC422.8, 
TH976.17, THRO.18, TRJO.58, TRO.11, UG037.8, WITO.33, ZM109.4, ZM135.10a, 
ZM197.7, ZM214.15, ZM249.1, ZM53.12). The correlations between the neutralization 
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patterns of the four longitudinal serum timepoints and the neutralization fingerprints of the 
reference antibodies were computed over a set of 28 HIV-1 strains (6535.3, AC10.29, 
CAAN.A2, CAP210.E8, CAP244.D3, CAP45.G3, DU156.12, DU172.17, DU422.01, PVO.
04, Q168.a2, Q23.17, Q259.17, Q461.e2, Q769.d22, Q842.d12, QH0692.42, REJO.67, 
RHPA.7, SC422.8, THRO.18, TRJO.58, TRO.11, WITO.33, ZM109.4, ZM135.10a, 
ZM197.7, ZM53.12). For the reference antibodies, data from multiple neutralization 
experiments was averaged and consolidated. All correlations are based on the Spearman 
rank coefficient.
Virus-like particle ELISA
VLP ELISAs were performed as described previously 31. Briefly, VLPs were produced by 
PEI-based cotransfection of 293T cells with a pCAGGS-based, Env-expressing plasmid and 
the Env-deficient HIV-1 genomic backbone plasmid pNL-LucR-E. VLPs were coated on 
ELISA wells at 20x the concentration in transfection supernatants. MAb binding was then 
assessed by ELISA, omitting detergent in PBS wash buffers and probing with an anti-human 
Fc alkaline phosphatase conjugate (Accurate, Westbury, NY) and SigmaFAST p-nitrophenyl 
phosphate tablets (Sigma). Plates were read at 405 nm.
Cell-surface Env Binding
293T cells were transiently transfected with plasmids encoding Env ZM53.12 or CAP256-
SU with deletions of the cytoplasmic tail 30. For binding experiments, after 2 days, the cells 
were stained with ViVid viability dye (Invitrogen) followed by serial dilutions of antibodies, 
two washes, then R-PE-conjugated F(ab) goat anti-human IgG specific for the Fc fragment 
(Jackson ImmunoResearch) at a 1:200 dilution54. For competition assays, the cells were 
stained with ViVid viability dye followed by biotinylated CAP256-VRC26.01 (10 μg/ml) or 
CAP256-VRC26.08 (0.8 μg/ml) premixed with serially diluted unlabeled competitor 
antibodies. After incubation and 2 washes, cells were stained with streptavidin-PE 
(Invitrogen) at 1:200 dilution. Cells were analyzed on a BD LSRII (Becton Dickinson). 
Binding was measured as the median fluorescence intensity (MFI) for each sample minus 
the MFI of cells stained with secondary antibody only.
Polyreactivity analysis of antibodies
Antibody binding to cardiolipin was determined as in 42. Briefly, using the QUANTA Lite 
ACA IgG III ELISA kit (Zeus Scientific) per manufacturer’s protocol, each antibody was 
diluted to 100 μg/ml in the kit sample diluent and tested in 3-fold serial dilutions. Results 
shown are representative of at least two independent ELISAs. Positive and negative controls 
were included on each plate, and values three times above background were considered 
positive. Antibody reactivity to a human epithelial cell line (HEp-2) was determined with 
the ANA/HEp-2 Cell Culture IFA Test System (Zeus Scientific) per manufacturer’s 
protocol, as described in42. Antibodies were diluted to 50 μg/ml and 25 μg/ml in ZOBRA-
NS diluent. Positive and negative controls were included on each slide. Antibodies were 
scored negative, indeterminate, or positive (1+ to 4+) at each dilution. Results are 
representative of at least two independent experiments.
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Electron Microscopy (EM) and Image Processing
VRC26.09 Fabs in complex with BG505 SOSIP.664 gp140 produced in HEK 293S cells 
were analyzed by negative stain EM. A 3 uL aliquot of ~8 ug/ml of the complex was applied 
for 15s onto a glow discharged, carbon coated 400 Cu mesh grid and stained with 2% uranyl 
formate for 20s. Grids were imaged using a FEI Tecnai T12 electron microscope operating 
at 120 kV using a 52,000 × magnification and electron dose of 25 e-/Å2, which resulted in a 
pixel size of 2.05 Å at the specimen plane. Images were acquired with a Tietz 4k × 4k CCD 
camera in 5° tilt increments from 0° to 50° at a defocus of 1000 nm using LEGINON55.
Particles were picked automatically by using DoG Picker and put into a particle stack using 
the Appion software package 56,57. Initial reference free 2D class averages were calculated 
using particles binned by 2 via the Xmipp Clustering 2D Alignment and sorted into 128 
classes58. Particles corresponding to the complexes were selected into a substack and 
another round of reference free alignment was carried out with unbinned particles using 
Xmipp Clustering 2D alignment and IMAGIC softwares 59. To generate an ab initio 3D 
starting model, a template stack of 44 images of 2D class averages was used without 
imposing symmetry. The resulting starting model was refined against 2D class averages for 
9 cycles and subsequently with 6,763 raw particles for 9 cycles using EMAN60. The 
resolution of the final reconstruction was calculated to be 28Å using an FSC cut-off value of 
0.5.
High-throughput sequencing
Amplicon for 454 next-generation sequencing was prepared as described 12,14 with slight 
modifications as indicated. Briefly, mRNA was prepared from 10–15 million PBMC using 
an Oligotex kit (Qiagen). cDNA was synthesized using Superscript II reverse transcriptase 
(Invitrogen) and oligo-dT(12–18) primers. Individual PCR reactions were performed with 
Phusion polymerase for 30 cycles. Primers (Supplementary Table 4) consisted of pools of 5–
7 oligonucleotides specific for all lambda gene families or VH3 family genes, and had 
adapters for 454 next generation sequencing. For week 176 only, heavy-chain PCR was 
performed with primers for all VH families, and mixed lambda and kappa primers were used 
for light chain (Supplementary Table 4). PCR products were gel-purified (Qiagen). 
Pyrosequencing of the PCR products was performed on a GSFLX sequencing instrument 
(Roche-454 Life Sciences, Bradford, CT, USA) on a half chip per reaction (full chips for 
week 176). On average, ~250,000 raw reads were produced.
High-throughput linkage of VH and VL transcripts was performed in single cell emulsions 
generated using a flow focusing apparatus35 (B.J.D., manuscript in preparation). CD27+ B 
cells were isolated from CAP256 PBMCs collected at 34, 48, 59, 69, and 119 weeks post-
infection by magnetic bead sorting (Miltenyi Biotec, Auburn, CA). Cells from weeks 34 and 
119 were divided in two groups and half of the cells were analyzed with FR1 primers35 
while the other half were analyzed with leader peptide primers41 (Supplementary Table 5). 
All other time points were analyzed in a single group using only FR1 primers 
(Supplementary Table 1). Overlap extension RT-PCR was performed as previously 
reported35, with extension time increased to 125 seconds. Nested PCR was performed as 
described previously with a 23-second extension time and PCR products were sequenced 
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using the Illumina 2×250 bp MiSeq platform. Raw reads were quality-filtered for an 
Illumina Q-score of 20 in 50% of bases. VRC26-class VH and paired VL sequences were 
identified via BLAST against CDR-H3 nucleotide sequences of the 12 culture-isolated 
antibodies.
Antibodyomics pipeline
Raw 454 data was processed using a pipeline implemented in Python, similar to one we 
reported previously 14. Briefly, reads were filtered for length, keeping only those between 
300 and 600 nucleotides. Germline V genes were then assigned to each read using BLAST 
with empirically optimized parameters. Reads for which no V gene match was found with an 
e-value ≤ 10-10 were discarded. For reads assigned to any VH3-30 or Vλ1-51 allele, (the 
CAP256-VRC26 germline genes), ClustalW2 61 was used to calculate the sequence identity 
to the germline and each isolated antibody. These data were plotted as density heat maps 
using ggplot2 in R to produce identity-divergence plots (Fig. 3b and Supplementary Fig. 4).
Finding clonally related sequences
Reads that were assigned to the same V genes as CAP256-VRC26, VH3-30 and Vλ1-51, 
were submitted to IMGT High-Vquest 62 (http://www.imgt.org/IMGTindex/IMGTHighV-
QUEST.html), and the results, including automated sequence corrections, were used to 
further sieve for lineage-related sequences. Reads assigned to J genes matching CAP256-
VRC26 (JH3 or Jλ1), and having similar divergence (+/− 15%) in the V and J genes, similar 
(+/− 10%) nucleotide and amino acid divergences in the V gene, and containing a 
continuous open reading frame throughout the entire variable region, were selected for 
further processing. Next, reads from all time points were pooled and clustered at 97.25% 
sequence identity (twice the standard deviation of expected 454 sequencing error) 14 using 
CDHit 63. For each cluster, a representative sequence was chosen from the earliest possible 
time point. The choice of cluster representatives from the earliest time points at which they 
appeared was critical to maintaining information on the chronology of lineage development 
in subsequent analyses. This procedure yielded 8,485 unique heavy chain and 6,410 unique 
light chain sequences.
To identify CAP256-VRC26 lineage-member heavy chains, we performed intra-donor 
phylogenetic analysis 14 on the unique 454 sequence set using the heavy chain sequences of 
the 12 isolated CAP256-VRC26 antibodies. 707 sequences were identified as likely lineage 
members, of which 27 were discarded after manual inspection, resulting in a total of 680 
unique CAP256-VRC26 lineage heavy chain sequences.
To identify light chain lineage members, a sieve requiring at least 92% sequence identity in 
CDR L3 to one of the isolated antibodies resulted in 495 sequences. Joinsolver 64 was used 
to examine the V-J junctions of these sequences in detail, to ensure that the recombination 
points matched those known for the isolated antibodies (Supplementary Fig. 5). This gave a 
total of 472 unique CAP256-VRC26 lineage light chain sequences.
Paired reads that were identified as members of the CAP256-VRC26 lineage were clustered 
using CDHit 63 at 95% sequence identity and consensus VH and VL sequences were 
generated for each cluster containing two or more pairs. Blast was then used to align the 
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resulting sequences to all clonally related sequences identified from the 454 sequencing as 
described above. Gapless alignments covering at least 190 nucleotides at 97% or greater 
sequence identity were considered to be matches. Two of the 157 paired sequences 
determined to be members of the CAP256-VRC26 lineage matched known CAP256-VRC26 
lineage sequences in both VH and VL 454 data sets. An additional 4 VH sequences and 1 
VL sequence were found in the 454 data, but their light or heavy chain partners were not 
present.
Computation of phylogenetic trees
Phylogenetic trees were constructed from 454 data and the sequences of antibodies isolated 
from B cell culture. Raw data is shown in Nexus format in Supplementary Figures 12 and 
13. MEGA5 65 was used to select the general time-reversible model with a gamma-
distributed rate parameter (GTR+G66) as the best mathematical model for building a 
maximum-likelihood tree from the CAP256-VRC26 lineage sequences. FASTML67 was 
then used to estimate the gamma parameter and build separate maximum likelihood trees for 
heavy and light chain sequences (including the isolated antibodies) and these were rooted on 
the germline V gene sequences. Two branches of the light chain tree were manually moved 
to match their positioning in the heavy chain tree based on the evidence from trees 
constructed solely with the 12 isolated antibodies. Analysis with DNAML from PHYLIP 
(Phylogeny Inference Package) version 3.6 (Felsenstein, J. 2005. PHYLIP (Phylogeny 
Inference Package) version 3.6. Distributed by the author. Department of Genome Sciences, 
University of Washington, Seattle) (http://cmgm.stanford.edu/phylip/dnaml.html) showed 
that these rearrangements did not significantly alter the log-likelihood score of the tree.
To create a condensed version of the heavy chain phylogenetic tree (Fig. 4c), CDR H3 
sequences were clustered using a 95% sequence identity threshold and requiring that all 
CDR H3s in a cluster have the same length. Isolated antibodies and monophyletic clusters 
with at least five members were represented by a single leaf, while all other sequences were 
removed from the tree. In cases were an internal node was deleted, branch lengths above and 
below that node were summed, so that the tree depths of all remaining sequences were 
maintained.
UCA and inferred intermediates
The phylogenetic trees of all heavy and all light chain lineage members calculated above 
(Fig. 3c and Extended Data Fig. 1) were input into the DNAML maximum likelihood 
software package to infer ancestral sequences. These are a direct consequence of the input 
sequences and the mathematical model used to build the trees; the gamma distribution found 
by FASTML above was used and the topology of the tree was held fixed, so no further 
information was added. The calculated heavy chain UCA was identical to the germline 
VH3-30*18 allele. Although the VH3-30*03 allele is only one nucleotide different from 
*18, germline sequencing of this donor showed that she carries the *18 allele and not the 
*03 allele (Cathrine Mitchell, personal communication). The inferred UCA is very similar to 
low-divergence sequences found in the week 38 data set (Extended Data Fig 6).
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To test intermediates in the development of CAP256-VRC26.01, two internal nodes were 
chosen from the phylogenetic trees to be approximately equally spaced in terms of 
evolutionary distance and the inferred sequences were retrieved using DNAML. Successful 
complementation of inferred heavy and light chains for each intermediate suggests that the 
lineage is well sampled by the 454 data and that the calculated phylogenetic trees 
successfully capture the coupled evolutionary dynamics of heavy and light chains.
Logograms for CDRH3s were made with Weblogo 68.
Protein Crystallization
VRC26.UCA Fab was prepared by digesting purified IgG with Lys-C at 37°C for 2 hours. 
The reaction was then quenched by the addition of cOmplete protease inhibitors (Roche). 
For VRC26.01, VRC26.03, VRC26.04, VRC26.06, VRC26.07 and VRC26.10 Fab 
preparation, an HRV3C recognition site (GLEVLFQGP) was inserted after Lys_235 and 
purified IgG was incubated with HRV3C protease overnight at 4 °C. For all, the digested 
antibodies were passed over Protein A agarose to remove the Fc fragment. The Fab was 
further purified over a Superdex 200 gel filtration column and concentrated aliquots were 
stored at −80°C. All Fabs were screened against 576 crystallization conditions using a 
Cartesian Honeybee crystallization robot. Initial crystals were grown by the vapor diffusion 
method in sitting drops at 20°C by mixing 0.2 μl of protein complex with 0.2 μl of reservoir 
solution. Crystals were manually reproduced in hanging drops by mixing 1.0 μl protein 
complex with 1.0 μl reservoir solution. VRC26-UCA was crystallized with a reservoir 
solution of 27% PEG 8000 and 0.1M Hepes pH 7.5 and was flash frozen in liquid nitrogen 
with 20% PEG 400 as a cryoprotectant. VRC26.01 was crystallized with a reservoir solution 
of 32% PEG 400, 4% PEG 3350 and 0.1M Na Acetate pH 5.5 and was flash frozen in liquid 
nitrogen with 20% ethylene glycol as a cryoprotectant. VRC26.03 was crystallized with a 
reservoir solution of 22% PEG 8000, 5% MPD and 0.1M imidazole pH 6.5 and was flash 
frozen in liquid nitrogen with 20% xylitol as a cryoprotectant. VRC26.04 was crystallized 
with a reservoir solution of 14% PEG 3350, 25% ispropanol and 0.1M Tris pH 8.5 and was 
flash frozen in liquid nitrogen with 20% ethylene glycol as a cryoprotectant. VRC26.06 was 
crystallized with a reservoir solution of 3M Na formate and 0.1M Tris pH 7.5 and was flash 
frozen in liquid nitrogen with 20% xylitol as a cryoprotectant. VRC26.07 was crystallized 
with a reservoir solution of 4% PEG 8000, 0.1M Zn acetate and 0.1M MES pH 6 and was 
flash frozen in liquid nitrogen with 20% glycerol as a cryoprotectant. VRC26.10 was 
crystallized with a reservoir solution of 22% PEG 4000, 0.4M Na Acetate and 0.1 M Tris pH 
7.5 and was flash frozen in liquid nitrogen with no cryoprotectant.
Data for all crystals were collected at a wavelength of 1.00 Å at SER-CAT beamlines ID-22 
and BM-22 (Advanced Photon Source, Argonne National Laboratory). All diffraction data 
were processed with the HKL2000 suite 69 and model building and refinement were 
performed in COOT 70 and PHENIX 71, respectively. For VRC26.03 Fab data, a molecular 
replacement solution consisting of one Fab molecule per asymmetric unit was obtained 
using PHASER with a search model from PDB ID 3F12. VRC26.03 then served as a search 
model for all remaining VRC26 Fabs. Throughout the refinement processes, a cross 
validation (Rfree) test set consisting of 5% of the data was used and hydrogen atoms were 
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included in the refinement model. Structure validations were performed periodically during 
the model building/refinement process with MolProbity 72. All graphical representations 
with protein crystal structures were made with Pymol 73.
Structure modeling on trimers
Defined locations of the V1V2, V3-glycan and CD4-binding sites were mapped directly 
onto EM density of the unliganded HIV-1 BAL spike (EMD-5019)50 using the software 
package UCSF Chimera 74. The CD4-binding site was defined by aligning density of the 
VRC01-bound BAL spike (EMD-5457)75 with the unliganded map and fitting a crystal 
structure of VRC01-bound gp120 (PDB id 3NGB)76 to the density. EM density in close 
proximity to the Fab structure was colored to highlight the region of contact. The same 
procedure was used to define the V3-glycan region using a PGT128-bound trimer 
(EMD-1970) and crystal structure (PDB id 3TYG)77 and the V1V2 region using the PG9-
bound BG505 SOSIP trimer (EMD-2241) 24 and a crystal structure of V1V2-bound PG9 
(PDB id 3U4E) 22. The fit of the PG9-V1V2 crystal structure to the SOSIP trimer was used 
to model the trimeric orientation of V1V2 using the 3-fold symmetry of the HIV-1 spike. 
The BG505.664 SOSIP crystal structure33 was presented to highlight the quaternary location 
of V1V2 point mutations. Side chains of residues 166 and 167, not seen in the crystal 
structure were modeled. The Man5 glycan at N160, also not seen in the crystal structure, is 
represented as in the crystal structure of the PG9-V1V2 complex (PDB id 3U4E).
Loop modeling
Two intermediates were calculated at approximately equal maturation distance along the 
VRC26-UCA to VRC26.01 pathway. Mutations associated with the intermediates were 
mapped directly onto the structure of VRC26.01. 14 of the 35 residues in the VRC26.01 
structure are disordered and were modeled with Loopy 78 (http://wiki.c2b2.columbia.edu/
honiglab_public/index.php/Software:Loopy) and represented as grey dots. Mutations of the 
intermediates were colored according to approximate time of occurrence based on the 
longitudinal phylogenetic tree highlighting the timeline of the structural development. 
These, and the other antibodies with modeled loops (Fig. 4), were modeled in a single loop 
prediction involving four steps. In the first step, Loopy was used to predict 10 loop 
conformations. The number of initial loop conformations to be sampled was set to 50,000 
(and the not the default value of 2,000). In the second step all 10 loop conformations were 
refined using the Protein Preparation Wizard in Maestro (http://www.schrodinger.com/). In 
the third step, sulfate groups were added to tyrosine at position 100 of the heavy chain and 
the entire structure was then subjected to all-atom energy minimization in Maestro. A fourth 
and final step was needed to ensure a reasonable sampling of the rotameric states for the 
sulfated tyrosines. The Rapid Torsion Scan module in Maestro was used to sample the chi 
angle involving the sulfate moiety in steps of 20 degrees. The model with the lowest energy 
after application of the Rapid Torsion Scan module was considered as the best prediction.
Tyrosine sulfation predictions were carried out in GPS-TPS (Z. Pan et al, http://
tsp.biocuckoo.org).
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Single Genome Amplification, Sequencing and Cloning
HIV-1 RNA was isolated from plasma using the Qiagen QIAamp Viral RNA kit, and 
reverse transcribed to cDNA using SuperScript III Reverse Transcriptase (Invitrogen, CA). 
The envelope genes were amplified from single genome templates 49 and amplicons were 
directly sequenced using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready 
Reaction kit (Applied Biosystems, Foster City, CA) and resolved on an ABI 3100 automated 
genetic analyzer. The full-length env sequences were assembled and edited using 
Sequencher v.4.5 software (Genecodes, Ann Arbor, MI). Multiple sequence alignments were 
performed using Clustal X (ver. 1.83) and edited with BioEdit (ver. 7.0.9) Sequence 
alignments were visualized using Highlighter for Amino Acid Sequences v1.1.0 (beta).
For analysis of selection pressure, and to account for recombination between the SU and PI, 
sequences were partitioned into two alignments (an SU-related, and a PI-related alignment) 
based on the inferred recombination breakpoints using an in-house script. Breakpoints were 
identified by a shift in identity from one reference towards the other, and required at least 
two sequential polymorphisms in common with a corresponding PI/SU-related virus in order 
to be considered. Phylogenies for both alignments were then reconstructed using FastTree79 
with a GTR+CAT model, and rooted on the PI/SU. Signals of selective pressure were 
detected with MEME (episodic diversifying selection)80 and DEPS (directional selection)81 
using the FastTree-generated trees, implemented in Hyphy 82.
The frequencies of specific amino acids at a site and the distribution of net charges in the V2 
epitope were calculated from the 2012 filtered web alignment (N=3990) from the Los 
Alamos HIV database (http://www.hiv.lanl.gov/).
Selected envelope amplicons were cloned into the expression vector pcDNA 3.1 
(directional) (Invitrogen) by re-amplification of SGA first-round products using Pfu Ultra II 
enzyme (Stratagene) with the EnvM primer, 5′-TAG CCC TTC CAG TCC CCC CTT TTC 
TTT TA-3′ 83 and directional primer, EnvAstop, 5′-CAC CGG CTT AGG CAT CTC CTA 
TGG CAG GAA GAA-3′ 48. Cloned env genes were sequenced to confirm that they exactly 
matched the sequenced amplicon. Autologous clones were mutated at key residues within 
the C-strand using the Stratagene QuickChange II kit (Stratagene) as described by the 
manufacturer. Mutations were confirmed by sequencing. Envelope clones were used to 
generate single round of replication Env-pseudoviruses as described above.
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Extended Data Figure 1. Sequences of CAP256-VRC26 heavy and light chains
Sequences of the 12 B-cell culture derived antibodies, inferred germline V and J genes, and 
inferred intermediates are compared to the predicted UCA. a, heavy chain. b, lambda light 
chain.
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Extended Data Figure 2. Neutralization breadth and potency of CAP256-VRC26 antibodies
a, Neutralization of autologous (CAP256 PI and SU) and 47 heterologous viruses by 
CAP256-VRC26 antibodies. Neutralization was measured using a TZM-bl assay with Env-
pseudoviruses. Geometric mean was calculated for values <50 mg/ml. b, Breadth-potency 
curves. Neutralization of a 194-virus panel was measured for VRC26.08, PG9, PGT145, and 
CH01. The curves show the percent of viruses neutralized at any given IC50.
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Extended Data Figure 3. CAP256-VRC26 antibodies recognize a quaternary epitope
a, All 12 CAP256-VRC26 mAbs were tested by ELISA against gp120 from ZM53 and 
CAP210. Positive control antibody PG9 bound to both gp120s (not shown). b, 23 proteins 
and scaffolded V1V2 constructs were tested by ELISA for binding of CAP256-VRC26.03 
and CAP256-VRC26.08. PG9 bound to several of these (not shown). Similar data were 
observed for CAP256-VRC26.06, .07 and .09. c, Binding of CAP256-VRC26.03 and 
CAP256-VRC26.08 to virus-like particles (VLP). VLP expressing ZM53, ZM53.K169E, 
CAP210, or no Env were concentrated by pelleting and used to coat ELISA plates; assays 
were performed without detergent to preserve the trimer spikes. Similar data were observed 
for CAP256-VRC26.06, .07 and .09.
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Extended Data Figure 4. Visualization of CAP256-VRC26.09 bound to Env trimers by negative-
stain electron microscopy
a, Raw micrograph and corresponding reference free 2D class averages of VRC26.09 in 
complex with cleaved soluble BG505 SOSIP.664 gp140 trimers. b, Projection matching of 
3D model refinement and FSC curve used to calculate resolution. Resolution, 28 Å at 
FSC=0.5. c, 3D reconstruction of VRC26.09:BG505 SOSIP.664 complex (green surface) 
alone and overlayed with PG9:SOSIP (purple mesh). The reconstructions are nearly 
identical in the trimer portion while displaying small differences in the Fab angles.
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Extended Data Figure 5. Effects of V2 mutations on neutralization activity of CAP256-VRC26 
antibodies
a, Each panel shows neutralization of wild-type and N160 glycan mutant CAP210.E8, 
ConC, KER2018.11, and ZM53.12 viruses. CAP256-VRC26 mAbs are partially and 
variably affected by loss of N160 glycan, in a virus-strain specific manner. In contrast, PG9-
class antibodies PG9, PGT142, and CH01 are uniformly knocked out by N160 mutation. b, 
CAP256-VRC26 mAbs are partially and variably affected by changes in V2 glycans. 
Neutralization by each antibody was measured against wild-type ZM32.12, mutants N156A 
and N160K, and ZM53.12 grown in the presence of kifunensine, an inhibitor of glycan 
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processing. In contrast to CAP256-VRC26 antibodies, PG9 activity is knocked out by the 
mutations and by kifunensine. c, HIV-6405 wild type is resistant to PG9 and CAP256-
VRC26 antibodies, while a PG9-sensitive mutant34 is also sensitive to CAP256-VRC26 
antibodies. d, Sequences of wild type and mutant HIV-6405.
Extended Data Figure 6. Origins of long CDRH3s in donor CAP256
a, Week 38 sequences from 454 that support the calculation of the UCA. Unique amino acid 
sequences with 2–5 residue changes in the CDR H3 are compared to the calculated UCA 
sequence. Each contained fewer than 3 combined nucleotide mutations in VH and JH. 
Parentheses, number of corresponding reads in the raw 454 data. b, c, Lack of autoreactivity. 
b, ELISA for binding to cardiolipin. 4E10 was strongly positive, CAP256-VRC26.03 was 
weakly positive, and the other 11 CAP256-VRC26 mAbs and the UCA were negative along 
with control antibody VRC01. c, Staining on Hep2 cells was assessed at 50 and 25 mg/ml. 
Only the positive control, mAb 4E10, showed positive staining. d, Distribution of CDRH3 
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lengths among 454 sequencing reads of B cell transcripts. The percentage of high-quality 
NGS reads that have CDR H3≥24 or ≥28 are shown for three HIV-1 uninfected donors 
(solid circles on both right and left plots) and for donor CAP256 (week 176) amplified with 
all-VH primers donor, and CAP256 (week 30) amplified with VH3 primers. High-quality 
reads are defined as successful V and J assignments and a continuous open reading frame. 
CDRH3 lengths use the IMGT definitions.
Extended Data Figure 7. Loss of flexibility at the base of the CDR H3
a, Top, logograms of CDR H3 sequences extracted from the heavy chain phylogenetic tree 
from weeks 59 and 119. The height of each letter is proportional its frequency in the 
population. Sequences that lack a disulfide bond contain a highly conserved glycine at the 
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3rd position of the CDR H3 (residue 97, Kabat definition). The appearance of the two 
cysteines that form the disulfide bond coincides with a glycine to arginine mutation at this 
site. (Bottom) Overlay and close-up of crystal structures from Supplementary Figure 6A. 
Loss of the glycine limits flexibility at the base of the CDR H3 and is shown in the crystal 
structures to be the initial site of divergence in the CDR H3 loops between the antibodies 
without the disulfide bond (UCA and CAP256-VRC26.01) and those with it (CAP256-
VRC26.03, .04, .06, .07, .10). This mutation may contribute to the conserved trajectory of 
the CDR H3 protrusion towards the heavy chain that is seen in the more mature antibody 
structures. b, CDRH3 and flanking sequences for VRC26.01, VRC26.03, and a mutant 
VRC26.03 in which the conserved cysteines are changed to the corresponding amino acids 
found in VRC26.01. c, neutralization activity of VRC26.03 and the mutant shown in panel 
b. The mutant shows reduced activity against CAP256 SU and complete loss of 
heterologous activity.
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Extended Data Figure 8. Viral polymorphisms and escape mutations
a, Frequency of CAP256 PI and SU polymorphisms at positions 160-162 (glycosylation 
sequon), 165, and 169. Colored slices on pie charts and percentages indicate prevalence of 
these polymorphisms within global circulating viruses in the Los Alamos Sequence 
Database (n=3,990). b, Distribution of net charge of the V2 epitope, defined as residues 160 
– 171, within global circulating viruses (n=3,990). The charge of the PI, SU and 176 week 
clones are indicated. c, CAP256-VRC26 mAb neutralization of the SU and PI viruses, and 
of the SU virus mutated to contain PI polymorphisms 162I, 165V or 169Q. d, CAP256-
VRC26 mAb neutralization of the SU virus mutated to contain known CAP256 escape 
mutations in the V2 epitope. e. CAP256-VRC26 mAb neutralization of 34 week clone 
(designated wildtype, wt) with an SU-like V1V2, compared to the I169K back mutant. (c–e) 
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The V2 epitope sequence, with mutated residues in red is shown on the left, IC50 values in 
the middle, and the time point when mutations were first detected in Env sequences on the 
right (weeks post-infection).
Extended Data Figure 9. Longitudinal changes in CAP256 V1V2
a, Variation in the V1V2 sequence of six Env clones. Amino acid mutations from residues 
160-171 are highlighted and corresponding changes in neutralization for the six Env clones 
by CAP256-VRC26.01-.12 and the UCA are shown. The charge of the displayed sequences 
that make up the central region of the trimer are shown on the right. b, Residue changes 
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highlighted in a were mapped onto the V1V2 domain in the crystal structure of the HIV-1 
BG505.664 SOSIP Env trimer. The structure is viewed looking towards the viral membrane 
along the trimer axis. Mutations are colored as in panel a and represented as spheres (amino 
acids) or stick and surface (glycan). c, Electrostatic surface representations of (top row) the 
full V1V2 region for each Env clone, (bottom row) Fabs. Timeline of infection is shown in 
the middle. V1V2 sequences were modeled with SWISS-MODEL using the BG505.664 
SOSIP as a template. Escape mutations R166S, K171N, and K169E resulted in a net charge 
change in the V2 epitope from +3 (SU) to a rare 0. Antibody CDR H3s became less 
negatively charged over time, suggesting co-evolution of the viral epitope and the antibody 
paratope.
Extended Data Table 1
Genetic characteristics of CAP256-VRC26 antibodies and V1V2-directed broadly 
neutralizing antibodies from other donors.
Data are from the present study and from references (Walker 2009, Walker 2011, 
Bonsignori2011JVI). CAP256-VRC26.01-12 are derived from B cell culture, while 
CAP256.VRC26-I1 and –I2 (in italics) are inferred intermediates. CDRH3 lengths use Kabat 
notation. a, nucleotides. b, amino acids.
a
Donor Antibody VH gene VL gene
% Divergence, Nucleotide




2% 4% 3% 8%
VRC26-I2 6% 7% 7% 13%
VRC26.01 8% 4% 11% 18%
VRC26.02 9% 5% 13% 27%
VRC26.03 9% 7% 13% 28%
VRC26.04 9% 8% 13% 28%
VRC26.05 10% 5% 13% 24%
VRC26.06 11% 7% 16% 30%
VRC26.07 12% 8% 14% 26%
VRC26.08 12% 10% 17% 33%
VRC26.09 14% 10% 19% 34%
VRC26.10 12% 4% 15% 26%
VRC26.11 12% 14% 18% 32%













IAVI84 PGT141 IGHV1-8*01 IGKV2-28*01 16% 13%
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Donor Antibody VH gene VL gene
% Divergence, Nucleotide






Donor Antibody VH gene VL gene CDRH3 Length
% Divergence, Amino Acid




35 6% 5% 8% 20%
VRC26-I2 35 11% 7% 13% 29%
VRC26.01 35 16% 7% 18% 40%
VRC26.02 35 16% 7% 27% 46%
VRC26.03 35 14% 9% 28% 46%
VRC26.04 35 14% 8% 28% 46%
VRC26.05 35 20% 8% 24% 40%
VRC26.06 36 18% 9% 30% 44%
VRC26.07 35 18% 9% 26% 46%
VRC26.08 37 16% 9% 33% 51%
VRC26.09 37 21% 7% 34% 54%
VRC26.10 35 17% 5% 26% 46%
VRC26.11 35 23% 23% 32% 49%










CH02 24 22% 23%
CH03 24 22% 19%





PGT142 32 30% 21%
PGT143 32 28% 22%
PGT144 32 31% 23%
PGT145 31 30% 26%
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Development of broad neutralization by donor CAP256 and isolation of neutralizing 
antibodies
(a) Timing of antibody isolation in relation to plasma neutralization titers against the 
primary infecting virus (PI), the superinfecting virus (SU), and a panel of 40 heterologous 
viruses (geometric mean titer shown). Percentage breadth (gray area), % of viruses 
neutralized with plasma ID50 >45. (b) Genetic characteristics and neutralization breadth and 
potency of the 12 isolated antibodies. Week of antibody isolation and V-gene mutation rates 
are indicated. Residues flanking the Kabat-defined CDR H3 sequences are shown in gray. 
Neutralization was assessed against a panel of 47 heterologous viruses. (c) Breadth and 
potency of antibody CAP256-VRC26.08 on a panel of 194 Env-pseudoviruses. Dendrogram 
shows phylogenetic relatedness of Env sequences in the panel.
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Figure 2. Mapping of CAP256-VRC26 epitope on the HIV-1 Env spike
(a) Left, correlations between neutralization fingerprints (see detailed methods) of CAP256-
VRC26 antibodies and CAP256 plasma. Darker gray indicates stronger correlation. Right, 
correlations between neutralization fingerprints of CAP256-VRC26 antibodies and 
representative antibodies targeting the major HIV-1 neutralization epitopes. Correlations are 
color-coded by antibody; darker shades indicate stronger correlations. (b) Competition 
assay. Binding to ZM53-Env-expressing 293T cells by labeled CAP256-VRC26.08 and 
unlabeled competitor antibodies measured by flow cytometry. Assay shown is representative 
of three experiments. (c) Left, negative stain electron microscopy (EM) 3D reconstruction of 
CAP256-VRC26.09 Fab in complex with soluble cleaved BG505 SOSIP.664 trimer; right, 
2D-class averages of VRC26.09 and PG9 in complex with BG505 SOSIP.664 trimer. (d) 
Neutralization of Env-pseudoviruses with HIV-ConC and V2 point mutants. Sequence 
shows amino acids 160-175. (e) Location of HIV-1 epitopes. Left, EM density of viral 
spike50, with viral membrane at top and major sites of vulnerability shown as determined by 
structural mapping of antibody interactions24. The gp41 membrane proximal external region 
(MPER) is shown schematically. Right, model of V1V2 based on EM reconstruction of PG9 
with BG505 SOSIP.664 trimer24,32, viewed looking towards the viral membrane along the 
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trimer axis. Green ribbon, strand C. V2 mutations from panel d are shown with surface 
representation; brighter green indicates more potent effects on neutralization.
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Figure 3. Maturation of the CAP256-VRC26 lineage revealed by NGS and VH:VL paired 
sequencing of B cell transcripts
(a) Timeline of longitudinal peripheral blood samples with quantification of total NGS 
sequence reads (total), and CAP256-VRC26 lineage-related reads (total and unique). Arrows 
below the line indicate time points of 454 pyrosequencing for heavy and light chain 
sequences. Circles indicate time points of paired sequencing of sorted B cells (see detailed 
methods). PCR amplifications for pyrosequencing used primers specific for VH3 family 
sequences (heavy chain) and V lambda sequences (light chain), with the exception of the 
week 176 sample (asterisk), which was amplified using all-VH gene primers, resulting in 
fewer CAP256-VRC26 specific reads. (b) Maturation time course for CAP256-VRC26.01 
(top panels) and CAP256-VRC26.08 (bottom panels). Heat map plots show sequence 
identity (vertical axis) versus germline divergence (horizontal axis) for NGS data. The 12 
isolated antibodies are displayed as red ‘x’s for reference, with the exception of the 
CAP256-VRC26.01 and 08 antibodies which are shown as black dots. Numbers between the 
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top and bottom panels correspond to the number of raw reads with at least 85% identity to 
the indicated antibody (top: VRC26.01, bottom: VRC26.08). (c) Phylogenetic trees of the 
CAP256-VRC26 clonal lineage for heavy chain (left) and light chain (right) were 
constructed by maximum likelihood using the 454 sequences and the isolated antibodies 
(black dots, labeled with antibody name). Branches are colored by time point when NGS 
sequences were first detected. The orange and blue circles indicate linked heavy and light 
chain sequences from the paired sequencing data. Scale, rate of nucleotide change (per site) 
between nodes.
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Figure 4. Structural characteristics of the developing CAP256-VRC26 lineage
(a) Crystal structure of the antigen-binding fragment (Fab) of CAP256-VRC26.03 shown in 
ribbon diagram representation. (b) Left, the intra-loop disulfide bond and tyrosine sulfation 
are shown in stick representation, and enlarged to show electron density (blue mesh, 2Fo-Fc 
at 1σ). Right, molecular surface, with electrostatic potentials colored red for acidic and blue 
for basic. CDR H3 regions of broadly neutralizing V1V2-directed antibodies are shown for 
comparison, with the left image in ribbon representation (tyrosine sulfates highlighted) and 
the right image in electrostatic representation. (c) Left, a condensed heavy chain 
phylogenetic tree highlights the isolated antibodies. Scale, rate of nucleotide change between 
nodes. The number of mutations to the heavy chain (H) and light chain (L) relative to the 
UCA are shown. Middle, structures of the variable regions. Mutations from the UCA are 
represented as spheres colored according to the week of antibody isolation at which the 
mutations first appear. Right, CDR H3 details. Residues that are (or evolve to become) 
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cysteines are labeled (gray dashes indicate modeled disordered regions). The position of 
tyrosines predicted to be sulfated (scores >1) are noted and were included in the formal 
charges shown for each CDR H3 and the electrostatic representations (far right).
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Figure 5. HIV-1 Env evolution and the development of the CAP256-VRC26 lineage
(a) V1V2 sequences are shown in highlighter format with the primary infecting virus (PI) 
designated as master and V2 residues 160 to 171 boxed. Asterisk at week 15 denotes 
sequences amplified with strain-specific primers matching the SU virus. (b) Logogram of 
the V2 epitope for all CAP256 sequences, with mutations away from the PI (master 
sequence) in color. (c) SU-like V1V2 sequences are indicated by black (present) and grey 
(absent) boxes. Escape mutations (K169E or R166S/K) are indicated by brown boxes. The 
net charge of the V2 epitope (residues 160 to 171) is shown in purple/white, ranging from 
+3 to 0. White lines separate clones within a time point; black lines separate time points. (d) 
Neutralization by the 12 CAP256-VRC26 mAbs of representative longitudinal Env clones 
isolated between 6 and 176 weeks post infection (weeks shown at far right). The CAP256 
mAbs are colored by time of isolation (as in Fig. 1). The development of the CAP256-
VRC26 antibody lineage, V1V2-directed plasma neutralizing antibodies, and plasma 
heterologous neutralization, are indicated on the right.
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Figure 6. Development from UCA to CAP256-VRC26.01
(a) Expanded view of the phylogenetic trees from Fig. 3c, highlighting the maturation 
pathway of CAP256-VRC26.01. Off-pathway branches were collapsed and are shown as 
dashed lines. Inferred intermediates VRC26-I1 and VRC26-I2 were expressed for functional 
analyses. (b–e) Binding and neutralization of antibodies UCA, VRC26-I1, VRC26-I2, 
VRC26.01. (b, d), Binding to cell-surface expressed Env (SU and ZM53). MFI, median 
fluorescence intensity. (c, e) Neutralization of (c) PI, SU and point mutants, and (e) seven 
heterologous viruses. Bars, standard error of the mean (triplicates). (f) Structural models of 
VRC26.01 lineage antibodies. Affinity matured residues are shown as spheres colored 
according to the intermediate at which they first appear: red, VRC26-I1; orange, VRC26-I2; 
green, VRC26.01. Grey dots, disordered residues in the CDR H3. The number of changes 
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from the UCA to each intermediate are noted for V gene only (VH or VL), or from the full 
UCA (UCA-HC or UCA-LC).
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